• After attending this presentation, learners will be able to:
    • Asses risk-benefit decision making in consideration of oral pre-exposure prophylaxis (PrEP) agents
    • Describe how to engage patients on a PrEP regimen
    • Describe the HIV prevention agents that are currently approved for PrEP

Dr. Gallegos has not relevant financial relationship to disclose.

Session date: 
10/10/2023 - 12:00pm to 1:00pm EDT
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 ANCC
    • 1.00 ANCC Pharmacology
  • 1.00 Participation
Please login or register to take this course.